Dr. Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.  He teaches clinical pharmacology to medical students and post-graduate students. He is an Adjunct Faculty of University of Florida, College of Pharmacy.

He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983.  He started working in the field of TDM since 1985 when he joined with Kyoto University Hospital as a faculty member responsible for TDM.  His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine.  Oncology and infectious diseases are his major fields for research.  He applied population pharmacokinetic and pharmacodynamic modeling to a number of new drug development as well as rational use of drugs for patient care such as clinical implementation of TDM.  Recently, he also investigates multi-omics biomarkers including pharmacogenomics, proteomics and metabolomics as a novel indicator to predict responder/non-responder variation to drug therapy.  He published more than 180 peer-reviewed original articles and 282 book chapters and review articles. He was distinguished as one of the “ISI Highly Cited Researchers” by Thomson Reuters ISI database.

He served as Secretary of the IATDMCT for 4 years, and Chair of the 15th Congress of IATDMCT in Kyoto, 2017.  He was a past President of Japanese Society of Therapeutic Drug Monitoring (JSTDM).

Employment

• 2016-present, Coordinator of the outpatient clinics for the management of polytherapies in HIV-infected patients, L. Sacco University Hospital, Milano, Italy
• 2004-2013, Component (Pharmacologist) of the Ethical Committee of the Scientific Institute E. Medea, Bosisio Parini, Lecco, Italy
• 2003-2008, Component (Pharmacologist) of the Ethical Committee of the Bolognini Hospital of Seriate, Bergamo, Italy
• 2004-2008, Head, Unit of Pharmacology and Pharmacogenetics, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
• 1997-2003, Research fellow, Mario Negri Institute for Pharmacological Research, Bergamo, Italy

Academic commitments

• 2010-present, Assistant professor in Pharmacology, Faculty of Medicine, University of Milano, Italy
• 2003-2011, Assistant Professor, Master in Transplant Medicine, University of Milano Bicocca, Italy
• 2005-2008, Educational coordinator, Maastricht University (Belgium), within the Research Elective Agreement with the Mario Negri Institute for Pharmacological Research, Bergamo, Italy
• 2004-2008, Assistant Professor, Master in Clinical Research, University of Milano, Italy
• 2013-2017, Assistant Professor, Master in Pharmacovigilance and Pharmacoepidemiology, University of Naples, Italy

Education & Certification:

• 1984-1989, High school diploma in Chemistry (Bergamo, Italy)
• 1990-1995, Pharmacy Degree (University of Milano, Italy)
• 1997-2000, Post-graduation specialization in Pharmacological Research (Mario Negri Institute for Pharmacological Research, Bergamo, Italy)
• 1998-2001, Post-degree Specialization in Pharmacology (University of Milano, Italy)
• 2001-2005, PhD in Biomedical Sciences (Open University, London, UK)

Professional Activities

• 2005-present, International Association of Therapeutic Drug Monitoring and Clinical Toxicology
• 2006-present, Italian Society of Pharmacology
• 2016-present, Italian Society of Infectious Diseases and Tropical Medicine
• 2019-present, European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
• 2009-2016, American College of Clinical Pharmacology
• 2018-present, Italian Federation of Human and Animal Mycology

Awards

• 2001, Winner of the E. Cofferati award for the research activity in the field of immunosuppressant pharmacology
• 2010, Winner of the D.E.I. Onlus Foundation award for the best emerging profiles in the field of clinical pharmacology

Publications / scientific activities

• Author of nearly 200 publications on peer reviewed indexed international journals, cited more than 5000 times, H-index: 35
• 7 book chapters
• Invited speaker for nearly 50 international congresses
• Invited speaker for nearly 200 national congresses
• Referee activities for dozens of indexed international journals (> 500 manuscripts reviewed)
• Member of the editorial board of European Journal of Drug Metabolism and Pharmacokinetics
• Member of the editorial board of Therapeutic Drug Monitoring
• Vice chair of the anti-infective committee within the IATDMCT society
• Member of the ESCMID PK/PD of Anti-Infectives Study Group
• Member of the board of directors of the Italian Federation of Human and Animal Mycology

Main clinical/research activities

• Therapeutic drug monitoring (mainly anti-infective agents, immunosuppressants, and central nervous system drugs)
• Pharmacokinetic studies both in healthy volunteers and in patients
• Application of pharmacogenetics as diagnostic tool for the optimization of drug therapies
• Antimicrobial stewardship
• Study and assessment of potential drug-drug interactions in real life settings
• Evaluation of potential inappropriate drug prescribing in fragile patients (deprescribing)
• Development and validation of analytical methods for the quantification of drugs in different biological matrices

Vision Statement
I envisage the future of the IATDMCT society as the key player for the tailoring of drug therapy in increasingly complicated patients (elderly, with comorbidities and heavy polypharmacy) at the bedside, taking advantage from the presence of active members with excellences and expertise in several fields. The accomplishment of this task requires, however, a day-by-day, two-way strict collaboration with specialists from different medical disciplines. In other words, the labs need to meet/match the clinics!

Dr. med. Maria Shipkova received her medical education at the Medical University, Sofia, Bulgaria, where she specialized in Laboratory Medicine. In 1992 she joined the TDM laboratory headed by Prof. Dobrin Svinarov, Chair for Clinical Laboratory, Sofia. In 1995 Dr. Shipkova was awarded a Tempus Phare postdoctoral fellowship from the European Union to broaden her education in therapeutic drug monitoring at the Department of Clinical Chemistry, Georg-August-University, Göttingen, under its Director, Prof Michael Oellerich. At the conclusion of this appointment she remained in Göttingen as a resident and was involved in a variety of routine and research activities in the field of transplantation and immunosuppressive drug monitoring. In 2003 Dr. Shipkova moved to Stuttgart, where she now pursues her work in the field of the therapeutic drug monitoring as a Senior Scientist at the institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart. She is responsible for the therapeutic drug monitoring/toxjcology section.

In 2005 Maria Shipkova was awarded with the Young Investigator Award of the International Society for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Her research interests are focused on drug metabolism & drug toxicity, development & evaluation of analytical methods, and most recently biomarkers as a tool to optimize immunosuppressive therapy.

Dr. Shipkova has authored over 100 peer- reviewed publications and has supervised several doctoral theses and post-doc fellows in the field of the therapeutic drug monitoring. She was the Chair of the IATDMCT immunosuppressive Drugs Scientific Committee (2013-2015) and IATDMCT Director of Education (2015 – 2017). Dr Shipkova is currently Vice-Chair of the Communications Committee of the IATDMCT. She has held the following positions: Coordinator "TDM of Everolimus" Consensus Project (2013-2016), Member of the IATDMCT Biomarkers in transplantation Working Group (2009 -), Associated member of the Bulgarian Academy of Science and Arts, past Editor in Chief of the IATDMCT Newsletter "Compass" (2009 - 2015).

Since September 2012, Denise has worked as a Forensic Toxicologist at Forensic Medicine and Science (FMS), University of Glasgow. Prior to this she worked for just under 10 years at Analytical Services International, St George’s - University of London under the supervision of IATDMCT Past-President Professor David W Holt. In both positions she has pursued her interest in bioanalytics; she specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds for application in the areas of forensic and clinical toxicology. In her current position Denise is also a reporting Forensic Toxicologist and Expert Witness responsible for interpretation and communication of toxicological finding to the Scottish Courts.

For 12 years, Denise has been an active member of IATDMCT with a successful committee history. During a decade on the Young Scientists Committee as Vice-Chair then Chair, YS membership increased from 8 to 296 members. Denise was also the founding chair of the very active Communications Committee, who are integral to association activities. Denise looks forward to devoting the same enthusiasm to her role as IATDMCT Treasurer.

Employment:

• Sep 2012-Present: Forensic Medicine and Science (FMS), University of Glasgow, UK
• Forensic Toxicologist

• Dec 2002-Sep 2012: Analytical Services International (ASI), St George’s, University of London, UK
  Senior Scientist in Clinical and Forensic Toxicology

Education & Certification:

• Sep 1996-June 2002: University of Strathclyde, Glasgow, UK
  MSci in Forensic and Analytical Chemistry

Professional Activities:

• Member of International Association of TDM & Clinical Toxicology (IATDMCT)
  Sep 2017-Present: Treasurer of IATDMCT
  Jan 2012-Dec 2017: Communications Committee (CC) Chair
  (activities coordinated by CC: E-News, Social Media, Blog, Website / Resources Area, Compass etc)
  Oct 2011-Oct 2015: Young Scientist Committee (YSC) Chair
  (coordinated all YS activities: Congress YS workshops/symposia, social events and awards, and all non-Congress educational activities)
  Sep 2007-Oct 2015: Compass Associate Editor
  Apr 2005-Oct 2011: Young Scientist Committee (YSC) Vice-Chair
• Member of The International Association of Forensic Toxicologists (TIAFT)
• Member of UK and Ireland Association of Forensic Toxicologists (UKIAFT)
• Member of London Toxicology Group (LTG)
• Member of Royal Society of Chemistry (MRSC)
• Invited speaker and presented at national and international meetings
• Contributed to to several peer-reviewed publications and book chapters
• Visiting Lecturer, Queen Mary, University of London (Oct-2010-Present)

Dr. Teun van Gelder is an internist-nephrologist and clinical pharmacologist. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time.

Between 2000 and 2019 he worked in the Departments of Hospital Pharmacy and Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands. In 2010, at Erasmus Medical Center he was appointed Professor in Clinical Pharmacology. His research at the Erasmus Medical Center was focused on clinical pharmacology and therapeutic drug monitoring. He was the chairman of the Dutch Society for Clinical Pharmacology & Biopharmacy, the secretary of the Dutch Society for Transplantation, and the President of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.

In December 2019 Teun van Gelder accepted a new position in Leiden University Medical Center (LUMC). He was appointed Professor in Drug Discovery & Development. LUMC, Leiden Institute of Chemistry, Leiden Academic Centre for Drug Research (LACDR), Centre for Human Drug Research (CHDR) and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development and testing of new innovative drugs. This environment is unique in the Netherlands, and provides an excellent basis for drug discovery and drug development. In his role as an experienced internist – clinical pharmacologist Teun will make an important contribution to Academic Pharma.

Current Appointments

• Senior Specialist in Clinical Microbiology and Infectious Diseases St. Vincent's Hospital, Sydney (1985 - to date)
• Clinical Director, Antimicrobial Therapeutic Drug Monitoring Group, St. Vincent’s Hospital, Sydney (2012 – to date)
• Visiting Medical Officer St. Vincent's Private Hospital, Sydney (1985 – to date)
• Visiting Medical Officer Sacred Heart Hospice, Sydney (1985 – to date)
• Conjoint Associate Professor, School of Medicine, University of New South Wales (2000 – to date)
• Adjunct Professor, Faculty of Science University of Technology, Sydney (2002 -to date)
• Associate Editor, Transplantation (2014 – to date)

Certifications

• Fellow of the Royal College of Pathologists of Australasia (FRCPA) 1986
• Fellow of the Royal Australasian College of Physicians (FRACP) 1985
• Bachelor of Medicine and Bachelor of Surgery, Honours Class I 1977
• Bachelor of Science (Medicine) Honours Class I 1974

Current Memberships - Professional Societies

• Royal Australasian College of Physicians
• Royal College of Pathologists of Australasia
• Australasian Society for Infectious Diseases
• Australasian Society for HIV Medicine
• American Society for Microbiology
• Australasian Society for Antimicrobials
• Infectious Diseases Society of America
• International Society for Heart and Lung transplantation
• International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• Transplant Infectious Diseases
• European Society for Clinical Microbiology and Infectious Diseases
• The Transplant Society
• Animal Management in Remote and Indigenous Communities

Selection of Professional Activities (all to date unless otherwise indicated)

• 1986- Member, Drug and Therapeutics Committee, St. Vincent's Hospital
• 1988 - Accreditor, National Association of Testing Authorities
• 1989-97 Member, N.S.W. State Committee, Royal Australasian College of Physicians
• 1990- Examiner, Royal Australasian College of Pathologists
• 1993 – 2014 Member, Tuberculosis Advisory Committee, N.S.W. Department of Health
• 1995 Visiting lecturer, University Santo Tomas, Manila, Philippines
• 1997-99 President, Australasian Society for HIV Medicine
• 2000-10 Member, Pharmacology and Toxicology Working Group, National Centre in HIV Epidemiology and Clinical Research
• 2009-13 Co-chair, Australian and New Zealand Mycoses Interest Group
• 2010 - Examiner, Royal Australasian College of Physicians
• 2012- Scientific Committee member (HIV and Infectious Diseases), International Association for Therapeutic Drug Monitoring and Clinical Toxicology
• 2012- Scientific Committee member, International Society for Heart and Lung Transplantation • 2012- Scientific Committee member, Transplant Infectious Diseases
• 2013- President, Transplant Infectious Diseases
• 2013- Board Member, Medical Advances without Animals
• 2014 - Visiting Lecturer, The Academy of Medicine, Singapore
• 2014- Visiting International Professor, Royal College of Pathologists of Australasia

• Approximately 160 publications in refereed journals
• Joint lead, IATDMCT Guidelines on TDM of Echinocandins
• Author, Therapeutic Drug Monitoring of Antifungal Agents Used in Patients Post Cardiothoracic Transplantation or with a Mechanical Circulatory Device. The 2014 International Society for Heart and Lunch Transplantation Guidelines for Management of Fungal Infections in Mechanical Circulatory Support and Cardiothoracic Organ Transplant Recipients. (In press).
• Proposer and Co-Convener – joint IATDMCT/TID/The Transplant Society (TTS) Conference, Hong Kong, 2016 in conjunction with TTS Conference
• Keynote and invited speaker at many national and international meetings including ICAAC (Denver 2012), IATDMCT (Salt Lake City 2012), ISHLT (Montreal, 2012; San Diego, 2013), The World Transplant Congress (San Francisco 2014), Transplant Infectious Diseases (Berlin, 2012; Vienna, 2013; Barcelona 2014), ISHAM (Melbourne 2015)
• Convener and speaker at a number of regional Mycology Master Classes run under the auspices of the International Society of Human and Animal Mycology (ISHAM) including Phuket (2011), Singapore (2012), Seoul (2013) and Penang (2014).
• Extensive connections with the Asian region and an invited speaker at many conferences within Asia, including Malaysia, Hong Kong, Singapore, Indonesia, Japan and China.
• Coordinator of the Clinical Stream at the forth-coming ISHAM conference in Melbourne (May 2015) and convener of the pre-congress workshop on Therapeutic Drug Monitoring in Fungal Infections.
• Reviewer of approximately 15 manuscripts per year for the past 5 years in local and international journals

Prof. Dr. Markus R. Meyer is a full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, Saarland University and head of the Department of Experimental and Clinical Toxicology at the Saarland University in Homburg, Germany. After he was promoted to PhD and gained his habilitation (venia legendi in pharmacology and toxicology) from the Saarland University, he moved to the Department of Clinical Pharmacology at the Karolinska Institutet in Stockholm, Sweden and thereafter to the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital, Germany. His main area of research is analytical toxicology including in-vitro and in-vivo toxicokinetics.

He has published over 120 peer-reviewed original papers or review articles and received several international and national scientific awards amongst them the TIAFT Achievement Award and the GTFCh Young Scientist Award. Besides IATDMCT, Prof. Meyer is member of several international and national scientific societies such as the TIAFT, GTFCh, DGPT, and DGMS.  He is currently IATDMCT board member and chair of the YS committee of the IATDMCT as well as vice chair of the TIAFT YS committee.

Staffan Rosenborg graduated as an MD from Karolinska Institutet in 1996. He became a specialist in Nephrology in 2003 and in Clinical Pharmacology in 2007. Dr Rosenborg defended his PhD thesis “CYP2C dependent drug metabolism in vivo – influence of genetics and drug interactions” in 2010. Prof Teun van Gelder was the external examiner.
Dr Rosenborg was Head of Residents and Director of post-graduate training in Clinical Pharmacology at the Karolinska University Hospital between 2010 and 2013. From 2013 he has been the Head of the Clinical Pharmacology Trial Unit (CPTU) at the same hospital. The CPTU is a phase-I trial unit certified for first-in-human trials. Dr Rosenborg was awarded the Swedish Diploma in Clinical Trials in June 2016.

He is the secretary of the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and is also one of two Swedish representatives in the Section for Pharmacology of the Union Européenne des Médecines Spécialistes (UEMS). He has more than 500 lecturing hours, has organized courses in clinical pharmacokinetics and has participated in courses on leadership in postgraduate education.

Dr Rosenborg has some 20 peer reviewed publications in international journals and some 15 papers in Swedish journals. His areas of expertise include: different aspects of nephropharmacology (including drug dosing in dialysis), immunosuppressive drugs, pharmacokinetics,  therapeutic drug monitoring, clinical trial design and conduct.

Dr. Ryuji Kato is an Associate Professor of Cardiovascular Pharmacotherapy and Toxicology at Osaka University of Pharmaceutical Sciences, Osaka, Japan. He completed his master’s degree in 2000 at Osaka University and began his career as a pharmacist at the Yokkaichi Social Insurance Hospital (Mie, Japan). He then moved to Osaka University of Pharmaceutical Sciences as an Assistant Professor. In 2008, he received his PhD in Pharmaceutical Sciences.

His research interests primarily include the appropriate use of pharmaceutical products. He has conducted extensive research on pharmacokinetics, drug-drug interactions (chelation complexes, drug-drug interactions on cytochrome P450 or via transporters), and serious adverse side effects (QT prolongation, drug induced liver injury, interstitial pneumonia, Stevens-Johnson syndrome, and toxic epidermal necrolysis).

He is the author or co-author of approximately 70 peer-reviewed manuscripts. Dr. Kato is a member of the following academic societies: International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Japanese Society of Therapeutic Drug Monitoring (JSTDM), Society of Toxicology (SOT), Pharmaceutical Society of Japan, and Japanese Society of Nephrology and Pharmacotherapy (JJNP). He has been a member of IATDMCT Communication Committee since 2015 and is an inspector for JSTDM.

Christophe Stove, PharmD, PhD, is Associate Professor at the Department of Bioanalysis at Ghent University (Belgium). After a cell and molecular biology-oriented PhD and postdoc, he embarked upon bioanalysis in 2007 and became head of the Laboratory of Toxicology at the Faculty of Pharmaceutical Sciences in 2014. Besides teaching several courses, he directs the Lab’s service activities (forensic toxicology and reference lab activities (Ref4U)) and steers the research. The latter covers applied cell biology, as well as bioanalysis, with topics linked to the development of bio-assays as an alternative drug screening approach in forensic toxicology, to vitamer analysis, or to microsampling applications and associated challenges. He has over 125 publications, many of which in leading journals, and has an h-index of 28. He is active as a Board/Council Member of several national and international organizations (including TIAFT and IATDMCT).

Nicolas Venisse got his PharmD from the University of Bordeaux, France in 1999. He completed his PhD in Pharmaceutical Sciences at the University of Poitiers. He also received accreditation to supervise research from the University of Poitiers. He is expert at the court of appeal of Poitiers.

He currently works at the Toxicology and Pharmacokinetics department at the University Hospital of Poitiers. He is also a member of the HEDEX (Health - Endocrine Disruptors – Exposome) research group at the Clinical Investigation Center of Poitiers (CIC INSERM 1402).

He is a member of several professional organizations including : Société Française de Pharmacologie et Thérapeutique and IATDMCT. He is the current chair of the Toxicology and Environmental Health scientific committee at IATDMCT. He is a member of the French National Academy of Pharmacy (Académie Nationale de Pharmacie), Environmental Health Committee (6éme section, Santé Environnementale).

He has over 40 peer-reviewed publications and 10 book chapters. His areas of expertise include: environmental toxicology, pharmaco- and toxico-kinetics, bioanalysis and PK/TK modeling.

Employment

• 01/2020 – present: Director of Toxicology Counseling Center of Hunan Province (TCCH), China
• 01/2019 – present: Deputy Director of Scientific Research Department, the Second Xiangya Hospital of Central South University, China
• 09/2017 – present: Associate Professor of Pharmacy, the Second Xiangya Hospital of Central South University, China
• 05/2013 – 06/2014: Postdoctoral Research Fellow, University of Illinois at Chicago, USA
• 07/2010 – 08/2017: Clinical Pharmacist, the Second Xiangya Hospital of Central South University, China

Education & Certification

• 2010: Ph.D. in Pharmacology, Central South University, China

Professional Activities

• Executive and committee positions held:
  • 09/2019 – present: Councilor of IATDMCT
  • 10/2018 – present: Chair of Young Scientist Committee, Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society (CHINA-TDM)
  • 09/2018 – present: Member of TDM in Oncology Committee, IATDMCT
  • 09/2016 – present: Member of Young Scientist Committee, IATDMCT
  • 07/2015 – present: Member of Pharmacometrics Committee, Chinese Pharmacological Society
• Activities in IATDMCT:
  • [Co-Chair of Symposium, Invited speaker]. IATDMCT Congress 2019; Sept 22-26, 2019, Foz do Iguassu, Brazil
  • [Executive chair]. The First CHINATDM-IATDMCT Young Scientist Joint Symposium at the 9th International Xiangya Clinical Pharmacy Forum; Sept 5-7, 2019, Changsha, China
  • [Guest speaker]. The Third JSTDM-IATDMCT Young Scientist Joint Symposium at the 36th Annual Meeting of the Japanese Society of Therapeutic Drug Monitoring; May 25-26, 2019, Tokyo, Japan
  • [Oral presentation]. IATDMCT Congress 2018; Sept 16-19, 2018, Brisbane, Australia
  • [Poster presentation]. IATDMCT Congress 2017; Sept 24-27, 2017, Kyoto, Japan
• Publications:
  • Published 50 research papers in Science Citation Index journals